ENANTA PHARMACEUTICALS INC Quarterly Operating Income (Loss) in USD from Q1 2012 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Enanta Pharmaceuticals Inc quarterly/annual Operating Income (Loss) history and growth rate from Q1 2012 to Q3 2024.
  • Enanta Pharmaceuticals Inc Operating Income (Loss) for the quarter ending September 30, 2024 was -$29.9M, a 3.79% increase year-over-year.
  • Enanta Pharmaceuticals Inc Operating Income (Loss) for the twelve months ending September 30, 2024 was -$122M, a 11.3% increase year-over-year.
  • Enanta Pharmaceuticals Inc annual Operating Income (Loss) for 2024 was -$122M, a 11.3% increase from 2023.
  • Enanta Pharmaceuticals Inc annual Operating Income (Loss) for 2023 was -$137M, a 10.8% decline from 2022.
  • Enanta Pharmaceuticals Inc annual Operating Income (Loss) for 2022 was -$124M, a 13% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$122M -$29.9M +$1.18M +3.79% Jul 1, 2024 Sep 30, 2024 10-K 2024-11-27
Q2 2024 -$123M -$24.2M +$12.5M +34.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$135M -$32.8M +$6.69M +16.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$142M -$34.9M -$4.87M -16.2% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-08
Q3 2023 -$137M -$31M -$3.98M -14.7% Jul 1, 2023 Sep 30, 2023 10-K 2024-11-27
Q2 2023 -$133M -$36.7M -$4.17M -12.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$129M -$39.5M -$5.6M -16.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$123M -$30M +$396K +1.3% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-08
Q3 2022 -$124M -$27M +$6.68M +19.8% Jul 1, 2022 Sep 30, 2022 10-K 2024-11-27
Q2 2022 -$131M -$32.5M +$1.31M +3.86% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$132M -$33.8M -$4.15M -14% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$128M -$30.4M -$18.1M -147% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-08
Q3 2021 -$110M -$33.7M -$13.9M -70.5% Jul 1, 2021 Sep 30, 2021 10-K 2023-11-22
Q2 2021 -$95.6M -$33.8M -$11M -48.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$84.6M -$29.7M -$17.8M -150% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$66.8M -$12.3M -$25.2M -196% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-10
Q3 2020 -$41.6M -$19.8M -$26.2M -408% Jul 1, 2020 Sep 30, 2020 10-K 2022-11-23
Q2 2020 -$15.4M -$22.9M -$26.6M -709% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $11.2M -$11.9M -$10.6M -811% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $21.8M $12.9M -$15M -53.8% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-09
Q3 2019 $36.7M $6.43M -$28M -81.3% Jul 1, 2019 Sep 30, 2019 10-K 2021-11-24
Q2 2019 $64.8M $3.76M -$18.9M -83.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $83.6M -$1.3M -$18.2M -108% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $102M $27.9M +$13.5M +93.8% Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-10
Q3 2018 $88.3M $34.5M -$19.8M -36.5% Jul 1, 2018 Sep 30, 2018 10-K 2020-11-25
Q2 2018 $108M $22.6M +$35.8M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 $72.4M $16.9M +$26.4M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q4 2017 $46M $14.4M +$21.4M Oct 1, 2017 Dec 31, 2017 10-Q 2019-02-08
Q3 2017 $24.6M $54.3M +$57.4M Jul 1, 2017 Sep 30, 2017 10-K 2019-11-27
Q2 2017 -$32.8M -$13.1M -$12M -1106% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 -$20.7M -$9.51M -$8.94M -1582% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 -$11.8M -$7.05M -$42.6M -120% Oct 1, 2016 Dec 31, 2016 10-Q 2018-02-09
Q3 2016 $30.8M -$3.1M -$6.77M -184% Jul 1, 2016 Sep 30, 2016 10-K 2018-11-29
Q2 2016 $37.6M -$1.09M -$2.79M -164% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $40.4M -$565K -$49.1M -101% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 $89.5M $35.6M -$34.6M -49.3% Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-09
Q3 2015 $124M $3.67M +$9M Jul 1, 2015 Sep 30, 2015 10-K 2017-12-11
Q2 2015 $115M $1.7M -$33.2M -95.1% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 $148M $48.6M +$53.7M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 $94.7M $70.2M +$75.7M Oct 1, 2014 Dec 31, 2014 10-Q 2016-02-09
Q3 2014 $19M -$5.33M -$625K -13.3% Jul 1, 2014 Sep 30, 2014 10-K 2016-12-09
Q2 2014 $19.6M $34.9M +$39.1M Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-10
Q1 2014 -$19.5M -$5.13M -$1.13M -28.1% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-08
Q4 2013 -$18.3M -$5.46M -$27.4M -125% Oct 1, 2013 Dec 31, 2013 10-Q 2015-02-06
Q3 2013 $9.03M -$4.7M Jul 1, 2013 Sep 30, 2013 10-K 2015-12-11
Q2 2013 -$4.18M -$650K -18.4% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-12
Q1 2013 -$4M -$36.1M -112% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-12
Q4 2012 $21.9M Oct 1, 2012 Dec 31, 2012 10-Q 2014-02-13
Q2 2012 -$3.53M Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-12
Q1 2012 $32.1M Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.